2500 Orteronel (Ort) maintenance therapy in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) and non-progressive disease after first-line docetaxel (Doc) therapy: Results of a multicenter randomized double-blind placebo-controlled phase III trial (SAKK 08/11)
Richard Cathomas(Kantonsspital Graubünden), Silke Gillessen(Institute of Oncology Research), S. Crabb, Sun Young Rha(Yonsei University), Simona Berardi Vilei(Swiss Group For Clinical Cancer Research), Nicholas W. Fischer(Hospital for Sick Children), Gabriela Manetsch(Kantonsspital Graubünden), Christian Rothermundt, Stefanie Hayoz(Swiss Group For Clinical Cancer Research), Heike Kenner(Swiss Group For Clinical Cancer Research), Michael Mark(Kantonsspital Graubünden), Tony Elliott(The Christie Hospital), Dominik Berthold(University Hospital of Lausanne), Andreas Erdmann(Kantonsspital Baden), Frank Stenner(University Hospital of Basel), Daniel Rauch(Washington University in St. Louis), Enrico Roggero, Philippe von Burg(Kantonsspital Aarau)
Cited by 0
Related Papers
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
|European Urology|2020|2.2k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k